AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SRTA

LAUCK ANDREW purchased $10K of SRTA

LAUCK ANDREW purchased 2,000 shares of Strata Critical Medical, Inc. (SRTA) at $5.00 on 2026-11-05.

Original reporting
SEC EDGAR · LAUCK ANDREW
Published Nov 9, 2026, 1:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SRTA
Neutral
medium confidence
Mentioned
$SRTA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRTANeutralLow
01

Why it matters

The filing provides a primary source of insider activity but the monetary amount is trivial.

02

Market read

Minor insider purchase with limited market impact; primarily of interest to existing shareholders.

03

What to watch

If the insider holds a larger undisclosed position, future purchases could become material.

Relevance 4/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$SRTANeutralMedium confidence
Context

Director Andrew Lauck bought 2,000 shares of Strata Critical Medical at $4.999 per share, totaling $9,998.

Expected impact

minimal upward pressure as market digests insider buying

Evidence & confidence

The transaction is a routine Form 4 filing with a modest $10K value; such small purchases rarely move the stock.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase is too small to indicate meaningful insider confidence; price may remain unchanged.

Key entities

  • company
    Strata Critical Medical, Inc.

    Medical device company issuing the Form 4.

  • person
    Andrew Lauck

    Director of Strata Critical Medical who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SRTA insider trading history →

Related articles

$SRTAMed

Strata Critical Medical (SRTA) Q3 2026 Earnings Call Transcript

Strata Critical Medical (SRTA) reported Q3 2026 earnings, exceeding guidance with 20% sequential revenue growth in clinical services, $8.6M in free cash flow, and $42M in cash. The company announced a $20M share repurchase program and expects high-teens organic EBITDA growth in 2027. Strata completed acquisitions and aims to deploy additional capital strategically.

finance.yahoo.com
$SRTAMed

Strata Critical Medical Q3 Earnings Call Highlights

Strata Critical Medical (SRTA) reported Q3 clinical gross profit up 18.3% sequentially, but gross margin declined to 25.6%. Logistics revenue fell 6.9% sequentially, while gross margin improved to 20.8%. The company expects higher margins in 2027. Strata ended the quarter with $41.6M in cash and authorized a $20M share repurchase. It reiterated 2026 guidance and expects high-teens organic adjusted EBITDA growth in 2027.

finance.yahoo.com
$SRTAMed

Strata Critical Medical Announces Third Quarter 2026 Results

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 November 3, 2026 Strata Critical Medical Announces Third Quarter 2026 Results • Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 • Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 • Q3 2026 net loss from continuing operations of $

SEC EDGAR 8-K
$SRTAMedAI 8/10

Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript

Strata Critical Medical (SRTA) reported Q2 2026 results, citing 15.1% sequential organic clinical revenue growth, with Transplant Clinical up 23.8%. Clinical gross margin rose to 26.1%. It generated $5.7M operating cash flow and $2.9M free cash flow. The company completed three bolt-on acquisitions and expects stronger cash generation in H2.

yahoo.com
$SRTAMed

Strata Critical Medical Announces Second Quarter 2026 Results

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clini

SEC EDGAR 8-K